Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430771 | 1.00 | HTR2C (0.49) | HTR2CESR2MAPTPDE4APDE4B | |
| SCHEMBL25227729 | 0.90 | HTR2C (0.51) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL25271583 | 0.90 | HTR2C (0.51) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL25224744 | 0.90 | HTR2C (0.51) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL10699999 | 0.83 | ESR2 (0.46) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL427824 | 0.82 | HTR2C (0.53) | HTR2CMAPT | |
| SCHEMBL715319 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL18980759 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL6891029 | 0.79 | HTR2C (0.59) | HTR2CESR2CYP1A2DDB1CRBN | |
| SCHEMBL5329450 | 0.79 | MAPT (0.57) | HTR2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349560-B1 | POLYMER-SUPPORTED TRANSITION METAL CATALYST COMPLEXES AND METHODS OF USE | UNIV KANSAS (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-102281948-B | The transition-metal catalyst complex compound of Polymer-supported and using method | UNIVERSITY OF KANSAS (US) | 2015-11-25 | — | — | CN | disclosed |
| US-8921486-B2 | Polymer-supported transition metal catalyst complexes and methods of use | UNIVERSITY OF KANSAS (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| CN-102281948-A | Polymer-supported transition metal catalyst complexes and methods of use | — | 2011-12-14 | — | — | CN | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110230620-A1 | Polymer-Supported Transition Metal Catalyst Complexes and Methods of Use | NATIONAL SCIENCE FOUNDATION | 2011-09-22 | — | — | US | disclosed |
| US-20110230620-A1 | Polymer-Supported Transition Metal Catalyst Complexes and Methods of Use | NATIONAL SCIENCE FOUNDATION | 2011-09-22 | — | — | US | disclosed |
| US-20110230620-A1 | Polymer-Supported Transition Metal Catalyst Complexes and Methods of Use | NATIONAL SCIENCE FOUNDATION | 2011-09-22 | — | — | US | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | HTR2C 240/4885ESR2 630/4885MAPT 2392/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | HTR2C 190/4885ESR2 554/4885MAPT 2573/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | HTR2C 240/4885ESR2 630/4885MAPT 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.